Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunosuppression in liver transplantation.

G T Everson1, J F Trotter, M Kugelmas

  • 1Division of Gastroenterology and Hepatology and Department of Medicine, University of Colorado School of Medicine, Denver, CO 80262, USA. greg.overson@uchsc.edu

Minerva Chirurgica
|November 7, 2003
PubMed
Summary

Immunosuppressive drugs effectively prevent liver transplant rejection but have side effects. Strategies like calcineurin-sparing regimens and steroid withdrawal can mitigate complications and improve outcomes for liver recipients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sensory Entrained TMS (seTMS) enhances motor cortex plasticity.

bioRxiv : the preprint server for biology·2025
Same author

Commentary on an article by Alberto Quintavalla & Klaus Heine. Recognizing the importance of the right to health as a prerequisite to rights hierarchization.

Ethics, medicine, and public health·2020
Same author

The Living Donor Collective: A Scientific Registry for Living Donors.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.

Journal of viral hepatitis·2017
Same author

All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database.

Alimentary pharmacology & therapeutics·2016
Same author

Editorial for Neuroendocrine Tumor for Liver Transplant.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation Medicine

Background:

  • Liver allograft rejection poses a significant risk to graft survival and patient mortality.
  • Current immunosuppressive medications are crucial for preventing rejection but are associated with dose-dependent side effects.
  • Calcineurin inhibitors (Cyclosporine, Tacrolimus) form the cornerstone of maintenance immunosuppression, often requiring modification to manage metabolic complications.

Purpose of the Study:

  • To review currently available immunosuppressive medications for hepatic allograft rejection.
  • To discuss strategies for managing side effects and optimizing immunosuppression.
  • To explore the impact of immunosuppression on post-transplant hepatitis C recurrence.

Main Methods:

  • Review of current literature on immunosuppressive medications in liver transplantation.

Related Experiment Videos

  • Analysis of strategies for managing drug toxicity and complications.
  • Discussion of approaches to post-transplant hepatitis C management.

    • Main Results:

    • Immunosuppressive medications are highly effective in preventing rejection, graft loss, and death.
    • Steroid withdrawal can ameliorate toxic effects without increasing rejection risk.
    • Calcineurin-sparing regimens (e.g., mycophenolate mofetil, sirolimus) allow for reduced calcineurin inhibitor doses.
    • Hepatitis C recurrence post-transplant is universal and aggressive, with no definitive immunosuppressive strategy proven to modify its course.

    Conclusions:

    • Tailoring immunosuppressive prescriptions based on ongoing advances in medications is essential for liver transplant recipients.
    • Managing side effects and addressing hepatitis C recurrence are key challenges in long-term liver transplant care.
    • Future developments in immunosuppressive and antiviral therapies hold promise for improved patient outcomes.